Clinical trial · Interventional
Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer
NCT00511992CI-TRIAL-00028364completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Ovarian Carcinoma | Ovarian Carcinoma | CURATED_BROADER | 0.78 |
| Ovarian Carcinosarcoma | Ovarian Carcinosarcoma | ONTOLOGY_EXACT | 0.98 |
| Primary Peritoneal Carcinoma | Primary Peritoneal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Avastin | Drug | Bevacizumab | ALIAS |
| Cisplatin | Drug | Cisplatin | ALIAS |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Avastin
- interventionNames
- Drug: Avastin
- Drug: Paclitaxel
- Drug: Cisplatin
Primary outcomes (1)
- measure
- Number of Patients Able to Complete 6 Cycles of Treatment.
- timeFrame
- 2 years
- description
- Completion of cycle 6
Secondary outcomes (1)
- measure
- Number of Patients Who Experienced Toxicities Associated With Intraperitoneal Cisplatin With Intravenous Paclitaxel and Avastin.
- timeFrame
- 2 years
- description
- CTCAE assessment of toxicity
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with stage II and III epithelial ovarian carcinoma, primary peritoneal carcinoma, or ovarian carcinosarcoma. * Adequate bone marrow, renal, and hepatic function * Patients must be entered no more than twelve weeks postoperatively Exclusion Criteria: * Patients with epithelial ovarian carcinoma of low malignant potential (borderline carcinomas). * Stage IV or suboptimally debulked disease following primary cytoreductive surgery * Patients who have received prior radiotherapy or chemotherapy.
References
Publications (0)
Data not yet available
No reference posted for this study.